Takayuki Yoshino

Research interests

Publications

• ctDNA-based molecular residual disease and survival in resectable colorectal cancer

  Nature Medicine · 2024 · https://doi.org/10.1038/s41591-024-03254-6

• Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer

  JAMA · 2023 · https://doi.org/10.1001/jama.2023.4428

• Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer

  Nature Medicine · 2023 · https://doi.org/10.1038/s41591-022-02115-4

• Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)00772-9

• Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.10.003

• Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00197-8

• ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.05.520

• CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer

  Cancer Science · 2021 · https://doi.org/10.1111/cas.14926

• Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.02088

• Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00086-3

• Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

  Nature Medicine · 2020 · https://doi.org/10.1038/s41591-020-1063-5

• Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2019.12.001

• Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.06.022

• Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2017699

• Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30527-1

• Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

  Journal of Clinical Oncology · 2019 · 10.1200/jco.19.02107

• Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1908075

• Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer

  International Journal of Clinical Oncology · 2019 · https://doi.org/10.1007/s10147-019-01485-z

• A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer

  Cancer Discovery · 2017 · https://doi.org/10.1158/2159-8290.cd-16-0795

• Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer

  International Journal of Clinical Oncology · 2017 · https://doi.org/10.1007/s10147-017-1101-6

• Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx738

• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

  Annals of Oncology · 2016 · https://doi.org/10.1093/annonc/mdw235

• Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1414325

• Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)70127-0

• Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

  The Lancet · 2012 · https://doi.org/10.1016/s0140-6736(12)61900-x

Current projects

No projects listed.